Crush Injury Clinical Trial
Official title:
Use of Hyperbaric Oxygen Therapy for the Treatment of Crush Injuries
Verified date | June 2022 |
Source | NYU Langone Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether using hyperbaric oxygen (HBO) improves wound healing for patients who have a crush injury. The comparison of the prospective intervention group to the retrospective matched cohort aims to show that HBO can improve wound healing and decrease poor outcomes for patients with crush injuries. The information gained from this small study will serve as a basis for a follow-up prospective, randomized control trial to further delineate the role of HBO in a larger patient population.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 2023 |
Est. primary completion date | September 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Presenting to NYU Winthrop Hospital with a crush injury of the extremity, including appendages, up to 14 days post injury. - No contraindication to hyperbaric oxygen therapy. - Able and willing to sign informed consent. Exclusion Criteria: - Critically-ill patient requiring intubation or pressor support. - Crush injury isolated to the distal phalanx (Tuft fracture). - Absolute contraindication to hyperbaric oxygen therapy (untreated pneumothorax). Relative contraindications (uncontrolled congestive heart failure, uncontrolled seizure disorder, pulmonary disease, claustrophobia) will be assessed by the treating physician. - Unable or unwilling to sign informed consent. |
Country | Name | City | State |
---|---|---|---|
United States | NYU Langone Health | New York | New York |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health | Winthrop University Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | healing measured by percentage of skin necrosis using a Bilateral Perfusion Index (BPI; TCOM of the affected limb/TCOM of the nonaffected limb). | week 2 | ||
Primary | healing measured by percentage of skin necrosis using a Bilateral Perfusion Index (BPI; TCOM of the affected limb/TCOM of the nonaffected limb). | week 6 | ||
Primary | healing measured by percentage of skin necrosis using a Bilateral Perfusion Index (BPI; TCOM of the affected limb/TCOM of the nonaffected limb). | week 24 | ||
Primary | healing measured by percentage of skin necrosis using a Bilateral Perfusion Index (BPI; TCOM of the affected limb/TCOM of the nonaffected limb). | week 52 | ||
Secondary | hospital length of stay | Number of days admitted over 52 weeks | 52 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06310265 -
Our Anesthesia Experiment Applied to Child Earthquake Victims in the February 6, 2023 Earthquake
|
||
Not yet recruiting |
NCT06003166 -
4-AP Peripheral Nerve Crossover Trial
|
Phase 3 |